Lumasiran治疗晚期1型原发性高草酸尿症:3期ILLUMINATE-C试验
ILLUMINATE-C是一项3期、开放标签、单臂、跨国研究,评估Lumasiran在晚期肾病1型原发性高草酸尿症(PH1)患者中的疗效与安全性。所有21例患者完成6个月主要分析期。主要终点:A组(未透析,n=6)血浆草酸盐(POx)最小二乘均值降低33.3%(95%CI -15.2%至81.8%),B组(透析,n=15)透析前POx降低42.4%(95%CI 34.2%至50.7%)。多数不良事件为轻中度,无患者停药或退出。
要点
- Lumasiran使未透析A组POx降低33.3%(95%CI -15.2%至81.8%),透析B组降低42.4%(95%CI 34.2%至50.7%)。
- 所有药效学次要终点均观察到改善,多数不良事件为轻中度。
- 最常见Lumasiran相关不良事件为注射部位反应,均为轻度且一过性。
核心结论
- Lumasiran在晚期肾病PH1患者中使POx大幅降低且安全性可接受,支持其在该人群中的疗效与安全性。
研究设计与样本
- 3期、开放标签、单臂、跨国研究,纳入各年龄段PH1患者,筛查时POx≥20 μmol/L,eGFR≤45 mL/min/1.73 m2(年龄≥12个月)或血清肌酐升高(年龄<12个月),包括伴或不伴全身性草酸盐沉积症患者。
- Lumasiran皮下给药,每月3次负荷剂量后按体重每月或每季度给药。
- 所有患者(N=21;43%女性;76%白人)完成6个月主要分析期,知情同意时中位年龄8岁(范围0-59岁)。
主要发现
- 主要终点:A组(入组时未接受血液透析,n=6)POx自基线至第6个月最小二乘均值降低33.3%(95%CI -15.2%至81.8%)。
- 主要终点:B组(入组时接受血液透析,n=15)透析前POx自基线至第6个月最小二乘均值降低42.4%(95%CI 34.2%至50.7%)。
- 所有药效学次要终点均观察到改善。
- 多数不良事件为轻中度,无患者停止治疗或退出研究。
- 最常见Lumasiran相关不良事件为注射部位反应,均为轻度且一过性。
局限性
- 单臂研究,无安慰剂对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and advanced kidney disease. STUDY DESIGN: Phase 3, open-label, single-arm trial. SETTING & PARTICIPANTS: Multinational study; enrolled patients with PH1 of all ages, estimated glomerular filtration rate ≤45 mL/min/1.73 m2 (if age ≥12 months) or increased serum creatinine level (if age <12 months), and POx ≥20 μmol/L at screening, including patients with or without systemic oxalosis. INTERVENTION: Lumasiran administered subcutaneously; 3 monthly doses followed by monthly or quarterly weight-based dosing. OUTCOME: Primary end point: percent change in POx from baseline to month 6 (cohort A; not receiving hemodialysis at enrollment) and percent change in predialysis POx from baseline to month 6 (cohort B; receiving hemodialysis at enrollment). Pharmacodynamic secondary end points: percent change in POx area under the curve between dialysis sessions (cohort B only); absolute change in POx; percent and absolute change in spot urinary oxalate-creatinine ratio; and 24-hour urinary oxalate adjusted for body surface area. RESULTS: All patients (N = 21; 43% female; 76% White) completed the 6-month primary analysis period. Median age at consent was 8 (range, 0-59) years. For the primary end point, least-squares mean reductions in POx were 33.3% (95% CI, -15.2% to 81.8%) in cohort A (n = 6) and 42.4% (95% CI, 34.2%-50.7%) in cohort B (n = 15). Improvements were also observed in all pharmacodynamic secondary end points. Most adverse events were mild or moderate. No patient discontinued treatment or withdrew from the study. The most commonly reported lumasiran-related adverse events were injection-site reactions, all of which were mild and transient. LIMITATIONS: Single-arm study without placebo control. CONCLUSIONS: Lumasiran resulted in substantial reductions in POx with acceptable safety in patients with PH1 who have advanced kidney disease, supporting its efficacy and safety in this patient population. FUNDING: Alnylam Pharmaceuticals. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04152200 and at EudraCT with study number 2019-001346-17. PLAIN-LANGUAGE SUMMARY: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by excessive hepatic oxalate production that frequently causes kidney failure. Lumasiran is an RNA interference therapeutic that is administered subcutaneously for the treatment of PH1. Lumasiran has been shown to reduce oxalate levels in the urine and plasma of patients with PH1 who have relatively preserved kidney function. In the ILLUMINATE-C study, the efficacy and safety of lumasiran were evaluated in patients with PH1 and advanced kidney disease, including a cohort of patients undergoing hemodialysis. During the 6-month primary analysis period, lumasiran resulted in substantial reductions in plasma oxalate with acceptable safety in patients with PH1 complicated by advanced kidney disease.
引用
- Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. Am J Kidney Dis. 2022. PMID: 35843439. doi:10.1053/j.ajkd.2022.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。